August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization (CRO) for MJP2, a Phase 2 study examining inhaled cannabis for the treatment of Posttraumatic Stress Disorder (PTSD) in Veterans. MJP2 is funded by a $12.9 million grant… Continue reading MAPS Partners with Changemark to Advance Cannabis PTSD Research for Veterans
